Zacks Investment Research·Oct 26, 2026
Is Medpace (MEDP) a Solid Growth Stock? 3 Reasons to Think "Yes"Medpace (MEDP) possesses solid growth attributes, which could help it handily outperform the market.
Medpace's premium positioning remains evidenced by a 23.1% operating margin in 2026Q3, roughly 1,100 basis points above ICON, and 31.3% gross margin recovery from the 27.8% trough in 2026Q1, driven by a richer small-biotech service mix and disciplined overhead leverage that lifted operating income 16.7% year over year…
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth slowed to 8.5% year over year in 2026Q3 from a 32.0% peak in 2025Q4, though gross margin recovered to 31.3% and operating income rose 16.7% to $165.5M on SG&A growth of just 7.7%, evidencing fixed-cost leverage cushioning the deceleration.
Medpace Holdings' full-service CRO model provides comprehensive clinical research solutions, driving efficiency and client retention.
The company's disciplined capital allocation and financial management have contributed to robust operational execution and stock appreciation.
Medpace Holdings is well-positioned to capitalize on the expanding biotech sector, leveraging its proprietary technology and expertise.
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 21, 2026 | $4.84+9.0% vs $4.44 | $716M+0.2% vs $714M |
Q3 2026 Jul 22, 2026 | $4.25+6.8% vs $3.98 | $707M+2.6% vs $690M |
Q2 2026 Apr 22, 2026 | $4.28+9.2% vs $3.92 | $707M+1.3% vs $698M |
Q1 2026 Feb 9, 2026 | $4.67+11.5% vs $4.19 | $708M+2.8% vs $689M |
Medpace (MEDP) possesses solid growth attributes, which could help it handily outperform the market.
Medpace (MEDP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Medpace Holdings is downgraded from "Buy" to "Hold" due to decelerating growth metrics and underwhelming forward guidance. Q3 2026 Net New Business Awards rose just 10.6%, a sharp slowdown from Q2's 28.2% growth, signaling weaker contract momentum. Revenue growth in Q3 2026 was 8.5% to $716M, below the prior quarter's 17.2% pace and only modestly above consensus.
Benchmark MEDP against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Medpace Holdings, Inc. (MEDP)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $653.11 | $18.23B | 35.78 | 19.97% | 18.24% | 99.76% | — | |
| $204.74 | $15.68B | 35.32 | -0.37% | 5.45% | 4.85% | — | |
| $337.52 | $16.26B | 408.03 | -0.85% | 1.01% | 1.3% | — | |
| $26.00 | $5.8B | -42.42 | 59% | -5.51% | -30.03% | — | |
| $271.83 | $44.74B | 32.57 | 5.87% | 8.05% | 21.39% | — | |
| $13.28 | $1.54B | -12.74 | 8.28% | -16.78% | -35.81% | — |
Medpace Holdings, Inc. (MEDP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Medpace Holdings, Inc. (MEDP) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 21, 2026·SEC
Jul 22, 2026·SEC
Jun 4, 2026·SEC
Get notified when MEDP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Medpace Holdings, Inc. (MEDP) stock FAQ — growth, dividends, profitability & financials explained
Medpace Holdings, Inc. (MEDP) reported $2.84B in revenue over the trailing twelve months. Revenue was $2.53B in fiscal year 2025. That is 772% more than the $290.0M of fiscal year 2014.
Medpace Holdings, Inc. (MEDP) grew revenue by 20.4% over the trailing twelve months, compared with the twelve months before.
Yes. Medpace Holdings, Inc. (MEDP) earned $517.8M in net income over the trailing twelve months (a 18.2% net margin).
Medpace Holdings, Inc. (MEDP) had a return on equity (ROE) of 99.8% over the trailing twelve months. That is well above the market's typical 10-15%.
Medpace Holdings, Inc. (MEDP) generated $667.6M in free cash flow over the trailing twelve months.
